Ebola.com Information about ebola and treatments.

  • Support Doctors Without Borders
  • Piroz, the ISIS Slayer, book
Sign In / Create User

  • HomeEbola.com
  • NewsBy Category
  • BasicsWhat Is Ebola
  • ResearchLatest Science
  • MediaVideos/Photos
  • FAQQuestions
  • ForumsDiscussions
  • Help Fight Ebola
  • Forums
  • Diseases Directory
  • Are You At Risk?
  • Cannabis a Cure?
  • Governmental Impact
  • Effect On Travel
  • Natural Remedy Ideas
  • Preparedness
  • Survival Tips
  • Map of Cases
  • TV / Movies / Entertainment
  • Enterovirus D68
  • Vaccine

Ebola vaccine gets $115M to speed development

January 16, 2015 Breaking News, Business News, Featured, Health News, Science News, World Newsebola, ebola outbreak, Ebola Vaccine, ebola virus, Vaccine, West Africa

Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe’s Innovative Medicines Initiative to speed development. The U.S. drug maker earlier this month announced it had started clinical trials of its two-injection vaccine, which uses a booster from Denmark’sBavarian Nordic, making it the third such product to enter human testing.

J&J began testing its Ebola-virus vaccine in humans earlier this month, with plans to have more than 400,000 doses available for large-scale clinical trials by April. J&J accelerated development of the vaccine regimen last fall as the Ebola virus continued to spread, overwhelming health-care systems across West Africa. The early-stage clinical trial is being led by the University of Oxford’s pediatrics department. J&J is also looking to launch mid-to-late-stage trials in Europe and Africa.

Health authorities and drug makers world-wide have been racing to develop treatments for those infected with the Ebola virus and vaccines to protect those not yet sickened. J&J’s vaccine proved safe and protective against the virus during testing in monkeys, which J&J Chief Scientific Officer Paul Stoffels said was normally a strong sign that the regimen would work in humans.

Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, are already in clinical development. J&J has been seeking partners after committing up to $200 million to accelerate its Ebola vaccine program in October.

The new initiative will see J&J join with institutions including the London School of Hygiene & Tropical Medicine, the University of Oxford and the Institut National de la Sante et de la Recherche Medicale to form consortia working on different aspects of vaccine development.

Chimerix started testing its Ebola drug on patients in Liberia earlier this month, in partnership with Oxford University and Doctors Without Borders.

 

Jan 16, 2015Atom
26 year old Dies of Sepsis after getting Flu5 Facts About the Threat of Nigeria’s Boko Haram vs Ebola

Leave a Reply Cancel reply

 

Subscribe

Sign up for our newsletter to receive the latest ebola news posts and a free ebook!

Your one stop source for ebola news from around the world, with treatment, health, and safety information. Google+

News Sources
  • Blogs & Links
  • Breaking News
  • Business News
  • Featured
  • Government News
  • Health News
  • Opinion News
  • Personal Safety
  • Science News
  • Travel
  • Treatments
  • USA News
  • World News
Subscribe

Sign up for our newsletter to receive the latest ebola news posts.

All Rights Reserved © 2014 / ebola.com / weedgrowthfund.com